

Vera Loizzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4314111/publications.pdf>

Version: 2024-02-01

97
papers

2,220
citations

236612

25
h-index

264894

42
g-index

99
all docs

99
docs citations

99
times ranked

2358
citing authors

#	ARTICLE	IF	CITATIONS
1	Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers. <i>Cancers</i> , 2022, 14, 365.	1.7	5
2	Management of a rare case of placenta trophoblast. <i>Minerva Obstetrics and Gynecology</i> , 2022, 74, .	0.5	2
3	The Application of Sonovaginography for Implementing Ultrasound Assessment of Endometriosis and Other Gynaecological Diseases. <i>Diagnostics</i> , 2022, 12, 820.	1.3	5
4	Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study. <i>Genes</i> , 2022, 13, 545.	1.0	8
5	Balloon Cell Melanoma: Presentation of Four Cases with a Comprehensive Review of the Literature. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 100-110.	0.7	4
6	Fertility sparing surgery in sex-cord stromal tumors: oncological and reproductive outcomes. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1063-1070.	1.2	9
7	Prognostic factors in clear cell carcinoma of endometrium: analysis of 55 cases.. <i>Acta Biomedica</i> , 2022, 92, e2021362.	0.2	2
8	Whose surgery is this? Endometriosis of the round ligament.. <i>Acta Biomedica</i> , 2022, 92, e2021375.	0.2	1
9	Fertility preservation techniques in cervical carcinoma. <i>Medicine (United States)</i> , 2022, 101, e29163.	0.4	3
10	A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 2143-2154.	0.8	9
11	Primitive Cutaneous (P)erivascular (E)pithelioid (C)ell Tumour (PEComa): A New Case Report of a Rare Cutaneous Tumor. <i>Genes</i> , 2022, 13, 1153.	1.0	3
12	Altered Gene Expression Encoding Cytokines, Growth Factors and Cell Cycle Regulators in the Endometrium of Women with Chronic Endometritis. <i>Diagnostics</i> , 2021, 11, 471.	1.3	15
13	HPV-Negative Cervical Cancer: A Narrative Review. <i>Diagnostics</i> , 2021, 11, 952.	1.3	18
14	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2020-002343.	1.2	4
15	Vascular and Cardiac Prognostic Determinants in Patients with Gynecological Cancers: A Six-Year Follow-up Study. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6091.	1.3	1
16	Peritoneal Tuberculosis Mimicking Ovarian Cancer: Gynecologic Ultrasound Evaluation with Histopathological Confirmation. <i>Gastroenterology Insights</i> , 2021, 12, 278-282.	0.7	7
17	Antibiotic therapy versus no treatment for chronic endometritis: a case-control study. <i>Fertility and Sterility</i> , 2021, 115, 1541-1548.	0.5	40
18	Dynamic crosstalk within the tumor microenvironment of uterine cervical carcinoma: baseline network, iatrogenic alterations, and translational implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103343.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Radiomics Analysis in Ovarian Cancer: A Narrative Review. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7833.	1.3	14
20	Artificial Intelligence in Dermatopathology: New Insights and Perspectives. <i>Dermatopathology (Basel, Switzerland)</i> , 2021, 8, 509-514.	0.7	20
21	Formalin-Fixed and Paraffin-Embedded Samples for Next Generation Sequencing: Problems and Solutions. <i>Genes</i> , 2021, 12, 1472.	1.0	15
22	Urological Melanoma: A Comprehensive Review of a Rare Subclass of Mucosal Melanoma with Emphasis on Differential Diagnosis and Therapeutic Approaches. <i>Cancers</i> , 2021, 13, 4424.	1.7	10
23	Blue mass in the pelvis: serous cystadenofibroma of the peritoneum. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, , .	0.9	4
24	A Machine Learning Tool to Predict the Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 823.	1.3	18
25	Dedifferentiated Melanoma: A Diagnostic Histological Pitfall—Review of the Literature with Case Presentation. <i>Dermatopathology (Basel, Switzerland)</i> , 2021, 8, 494-501.	0.7	8
26	954â€¦A Machine Learning Approach Applied to Gynecological Ultrasound to Predict Progression-Free Survival in Ovarian Cancer Patients. , 2021, , .		0
27	Skin Mycetoma in an 11-Year-Old African Boy: Case Presentation with Emphasis on Histopathological Features and Differential Diagnosis. <i>Dermatopathology (Basel, Switzerland)</i> , 2021, 8, 509-514.	0.7	1
28	GLUT1, GLUT3 Expression and 18FDG-PET/CT in Human Malignant Melanoma: What Relationship Exists? New Insights and Perspectives. <i>Cells</i> , 2021, 10, 3090.	1.8	5
29	The Role of Ultrasound Guided Sampling Procedures in the Diagnosis of Pelvic Masses: A Narrative Review of the Literature. <i>Diagnostics</i> , 2021, 11, 2204.	1.3	3
30	Germinal ovarian tumors in reproductive age women. <i>Medicine (United States)</i> , 2020, 99, e22146.	0.4	19
31	Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery. <i>Biomedicines</i> , 2020, 8, 554.	1.4	16
32	Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel. <i>Supportive Care in Cancer</i> , 2020, 28, 2435-2442.	1.0	5
33	PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	16
34	Management of abdominal wall recurrent subfascial seroma after pelvic surgery. <i>Acta Biomedica</i> , 2020, 91, e2020092.	0.2	0
35	Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study. <i>European Journal of Cancer Care</i> , 2019, 28, e13137.	0.7	9
36	Human Ovarian Cancer Tissue Exhibits Increase of Mitochondrial Biogenesis and Cristae Remodeling. <i>Cancers</i> , 2019, 11, 1350.	1.7	40

#	ARTICLE	IF	CITATIONS
37	Chronic Endometritis, a Common Disease Hidden Behind Endometrial Polyps in Premenopausal Women: First Evidence From a Case-Control Study. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 1346-1350.	0.3	43
38	Pregnancy related cancer in Apulia. A population based linkage study. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology</i> : X, 2019, 3, 100025.	0.6	8
39	The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2401.	1.8	67
40	Increased human Chorionic Gonadotropin levels five years before diagnosis of an ovarian dysgerminoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 220, 138-139.	0.5	4
41	A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer. <i>Journal of Chemotherapy</i> , 2018, 30, 247-252.	0.7	4
42	Mitochondrial Dysfunctions in Type I Endometrial Carcinoma: Exploring Their Role in Oncogenesis and Tumor Progression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2076.	1.8	12
43	BRCAmut and "founder effect", a prospective study in a single academic institution. <i>Oncotarget</i> , 2018, 9, 22353-22358.	0.8	9
44	Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases. <i>Oncology</i> , 2017, 92, 197-204.	0.9	12
45	Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 285-287.	0.4	18
46	Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1967.	1.8	68
47	Surgicel® granuloma mimicking ovarian cancer: A case report. <i>Oncology Letters</i> , 2016, 12, 1083-1084.	0.8	13
48	Goblet-cell carcinoid of the ovary: A case report with ultrastructural analysis. <i>Journal of Obstetrics and Gynaecology</i> , 2016, 37, 1-2.	0.4	4
49	Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). <i>Gynecologic Oncology</i> , 2016, 143, 532-538.	0.6	43
50	Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature. <i>Oncology</i> , 2016, 91, 211-216.	0.9	10
51	Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study. <i>Gynecologic Oncology</i> , 2016, 143, 276-280.	0.6	40
52	Borderline epithelial tumors of the ovary: Experience of 55 patients. <i>Oncology Letters</i> , 2015, 9, 912-914.	0.8	17
53	A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. <i>Journal of Obstetrics and Gynaecology</i> , 2015, 35, 758-760.	0.4	6
54	Unsuspected diagnosis of uterine leiomyosarcoma after laparoscopic myomectomy. <i>Journal of Obstetrics and Gynaecology</i> , 2015, 35, 211-212.	0.4	3

#	ARTICLE	IF	CITATIONS
55	A case of sarcoidosis mimicking recurrences of endometrial cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2015, 35, 540-542.	0.4	1
56	Bowel Dysfunction following Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Prospective Study. <i>Oncology</i> , 2014, 86, 239-243.	0.9	5
57	The impact of lymph vascular space invasion on recurrence and survival in patients with early stage endometrial cancer. <i>European Journal of Cancer Care</i> , 2014, 23, 380-384.	0.7	15
58	Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study. <i>Gynecologic Oncology</i> , 2013, 130, 505-510.	0.6	19
59	Small cell carcinoma of the uterine cervix metastasising to the cerebellum. <i>Journal of Obstetrics and Gynaecology</i> , 2013, 33, 639-640.	0.4	1
60	Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium. <i>BMC Research Notes</i> , 2012, 5, 279.	0.6	33
61	Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994. <i>International Journal of Gynecology and Obstetrics</i> , 2011, 114, 133-136.	1.0	20
62	Central Nervous System Metastases From Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 816-821.	1.2	19
63	Prognostic Factors and Outcomes in 28 Cases of Uterine Leiomyosarcoma. <i>Oncology</i> , 2011, 81, 91-97.	0.9	17
64	Carcinosarcoma of the Ovary: Analysis of 13 Cases and Review of the Literature. <i>Oncology</i> , 2011, 80, 102-106.	0.9	24
65	Locally advanced cervical cancer associated with complete uterine prolapse. <i>European Journal of Cancer Care</i> , 2010, 19, 548-550.	0.7	13
66	Groin recurrence in carcinoma of the vulva: management and outcome. <i>European Journal of Cancer Care</i> , 2010, 19, 302-307.	0.7	44
67	Carcinosarcoma of the vulva: A case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2010, 36, 705-708.	0.6	7
68	Lymphadenectomy Versus No Lymphadenectomy in Endometrial Carcinoma: A Retrospective Analysis of 410 Patients. <i>Journal of Gynecologic Surgery</i> , 2010, 26, 93-98.	0.0	3
69	Cisplatin and Vinorelbine Chemotherapy in Recurrent Vulvar Carcinoma. <i>Oncology</i> , 2009, 77, 281-284.	0.9	38
70	The PGC-1 α -dependent pathway of mitochondrial biogenesis is upregulated in type I endometrial cancer. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 1182-1185.	1.0	65
71	Spleen involvement in women with ovarian cancer. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2009, 30, 384-6.	0.3	2
72	Neoadjuvant Chemotherapy: An Alternative Option of Treatment for Locally Advanced Cervical Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2008, 65, 96-103.	0.7	31

#	ARTICLE	IF	CITATIONS
73	Leptomeningeal involvement after remission of brain metastases from ovarian cancer. International Journal of Gynecology and Obstetrics, 2007, 99, 139-139.	1.0	6
74	A case of Sertoli-Leydig cell tumor in a postmenopausal woman. International Journal of Gynecological Cancer, 2006, 16, 435-438.	1.2	19
75	Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience. International Journal of Gynecological Cancer, 2006, 16, 631-637.	1.2	26
76	A rare case of choroidal metastasis presented after conservative management of endometrial cancer. International Journal of Gynecological Cancer, 2006, 16, 2044-2048.	1.2	33
77	Two Cases of Endometrial Cancer Diagnosis Associated with Bone Metastasis. Gynecologic and Obstetric Investigation, 2006, 61, 49-52.	0.7	22
78	Non-Puerperal Uterine Inversion due to Uterine Sarcoma. Gynecologic and Obstetric Investigation, 2006, 61, 171-173.	0.7	12
79	Clinicopathologic features of six cases of primary cervical lymphoma. American Journal of Obstetrics and Gynecology, 2005, 193, 866-872.	0.7	51
80	Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. International Journal of Gynecological Cancer, 2005, 15, 217-223.	1.2	51
81	Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?. International Journal of Gynecological Cancer, 2005, 15, 420-425.	1.2	4
82	Clinical features of hepatic metastasis in patients with ovarian cancer. International Journal of Gynecological Cancer, 2005, 15, 26-31.	1.2	19
83	Prognostic factors responsible for survival in sex cord stromal tumors of the ovaryâ€”A multivariate analysis. Gynecologic Oncology, 2005, 96, 204-209.	0.6	88
84	Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii. Gynecologic Oncology, 2005, 97, 282-284.	0.6	42
85	Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecologic Oncology, 2005, 99, 20-25.	0.6	87
86	Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. International Journal of Gynecological Cancer, 2005, 15, 217-223.	1.2	37
87	Differences in Prognostic Molecular Markers between Women Over and Under 45 Years of Age with Advanced Ovarian Cancer. Clinical Cancer Research, 2004, 10, 8538-8543.	3.2	25
88	Rapid growth of myxoid leiomyosarcoma of the vulva during pregnancy: a case report. International Journal of Gynecological Cancer, 2004, 14, 172-175.	1.2	33
89	Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecologic Oncology, 2004, 92, 368-371.	0.6	20
90	Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assayâ€”guided chemotherapy. American Journal of Obstetrics and Gynecology, 2003, 189, 1301-1307.	0.7	83

#	ARTICLE	IF	CITATIONS
91	Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2003, 90, 181-185.	0.6	153
92	Prognostic factors in neuroendocrine small cell cervical carcinoma. <i>Cancer</i> , 2003, 97, 568-574.	2.0	188
93	Chemoradiation: A new approach for the treatment of cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 580-586.	1.2	23
94	Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. <i>Obstetrics and Gynecology</i> , 2003, 102, 156-161.	1.2	53
95	Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. <i>Journal of reproductive medicine, The</i> , 2003, 48, 756-60.	0.2	24
96	An unusual presentation of struma ovarii mimicking a malignant process. <i>Obstetrics and Gynecology</i> , 2002, 100, 1111-1112.	1.2	13
97	The value of ultrasonographic examination of the uterine cervix in predicting post-term pregnancy. <i>Journal of Perinatal Medicine</i> , 2001, 29, 317-21.	0.6	23